The effect of MYO18B mRNA suppression was stronger in bFGF treated conditions (Fig. 3C), which stand in line with the negative correlation of FGF2 with MYO18B in HCC patients (Fig. 3A). This evidence concerns the gene MYO18B and hepatocellular carcinoma.